Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5D11D4 is a **mouse IgG1 monoclonal antibody** directed against **placental growth factor** and used as a **preclinical biologic research therapeutic**. It inhibits the **PlGF and neuropilin 1 signaling axis**, a pathway implicated in angiogenesis, tumor growth, inflammatory cell recruitment, and fibrotic wound healing. In the literature provided, 5D11D4 was supplied by **ThromboGenics** and investigated in animal models of **medulloblastoma**, **glaucoma filtration surgery failure**, and **wound healing/scarring**, where it showed antitumor, anti-angiogenic, and anti-fibrotic effects. The available evidence supports that this agent remained an experimental research antibody rather than a clinically developed marketed drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5D11D4.